organization · Reporting owner
ELITE PHARMACEUTICALS INC /NV/
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ELITE PHARMACEUTICALS INC /NV/ELTP · Entity 5936 | EVP Operations | August 22, 2025 | August 26, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ELITE PHARMACEUTICALS INC /NV/
Report date August 22, 2025 · Filed August 26, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,300,000 |
Ending reported balance
After 2025-08-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-08-22 · Sale · Disposed 500,000 · Balance 1,800,000 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.52 to $0.56, inclusive. The reporting person undertakes to provide to Elite Phannaceuticals, any security holder of Elite Pharmaceuticals, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote(1) to this Form 4 Row 2 · 2025-08-25 · Exercise / conversion · Acquired 2,500,000 · Balance 4,300,000 |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2033-01-03 | Direct | 2,500,000 |
Reported balance
After 2025-08-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-08-25 · Exercise / conversion · Disposed 2,500,000 · Balance 2,500,000 F2: All of the stock options were fully vested and exercisable as of the transaction date. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.52 to $0.56, inclusive. The reporting person undertakes to provide to Elite Phannaceuticals, any security holder of Elite Pharmaceuticals, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote(1) to this Form 4
F2: All of the stock options were fully vested and exercisable as of the transaction date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 25, 2025 Filed Aug 26, 2025 21:17 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | Exercise / conversionStock Options (right to buy) · Derivative | 2,500,000 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001493152-25-012347 · ownership.xml · derivative · entry 3 ELITE PHARMACEUTICALS INC /NV/ · CIK 0001053369 · EVP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500,000 Underlying: Common Stock · 2,500,000 shares Expires 2033-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of the stock options were fully vested and exercisable as of the transaction date. Read SEC document |
| August 25, 2025 Filed Aug 26, 2025 21:17 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | Exercise / conversionCommon Stock | 2,500,000 | $0.03 | $75,000.00 |
DisclosureSEC source: 0001493152-25-012347 · ownership.xml · nonDerivative · entry 2 ELITE PHARMACEUTICALS INC /NV/ · CIK 0001053369 · EVP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,300,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 21:17 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | SaleCommon Stock | 500,000 | $0.52 | $262,150.00 |
DisclosureSEC source: 0001493152-25-012347 · ownership.xml · nonDerivative · entry 1 ELITE PHARMACEUTICALS INC /NV/ · CIK 0001053369 · EVP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,800,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.52 to $0.56, inclusive. The reporting person undertakes to provide to Elite Phannaceuticals, any security holder of Elite Pharmaceuticals, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote(1) to this Form 4 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.